U.S. Hotel and Resort REITs Stock News

In March 2026, Marsh announced that Nick Studer will become President and CEO of Marsh Risk on April 1, 2026, succeeding Martin South, who moves into an enterprise-wide role as Chief Client Officer while both remain on the Executive Committee reporting to John Doyle. This leadership reshuffle strengthens Marsh’s focus on client impact and innovation, bringing Oliver Wyman’s consulting expertise closer to the core risk business while a new Oliver Wyman CEO is named. Next, we’ll examine how...

In recent weeks, CCM Hockey and Mattel announced the launch of an all-new Barbie x CCM Collection of performance hockey gear and apparel aimed at making the sport more inclusive and expressive for a new generation of girls and athletes. This collaboration highlights Mattel’s broader push to extend the Barbie brand beyond traditional toys into sports and lifestyle, aligning with its ambition to build a wider entertainment and consumer-products platform. We’ll now look at how this inclusive...

ORIC Pharmaceuticals (ORIC) came under pressure after Ipsen pulled cancer drug Tazverik over concerns about secondary hematologic malignancies, even though ORIC said its prostate cancer candidate rinzimetostat showed no malignancies in preclinical toxicity testing. See our latest analysis for ORIC Pharmaceuticals. At a share price of US$11.90, ORIC has seen a 19.12% 30 day share price return and 45.65% year to date. The 1 year total shareholder return of 52.76% and 3 year total shareholder...

Simmons First National (NasdaqGS:SFNC) reported quarterly results that exceeded revenue and EPS expectations. The bank highlighted resilient operations and solid performance within its regional banking footprint. The update adds fresh information on the company’s current business momentum that has not been reflected in recent coverage. Simmons First National, trading at $18.61, has delivered a quarter that came in ahead of both revenue and earnings forecasts, which puts a fresh spotlight on...

Recent share performance context Ross Stores (ROST) has drawn investor attention after its shares delivered a 68.3% total return over the past year, along with a 12.9% gain year to date and a 12% return in the past 3 months. See our latest analysis for Ross Stores. At a share price of US$206.28, Ross Stores has recently eased back over the past week even after a solid 30 day share price return, while its 1 year total shareholder return of 68.3% and 3 year total shareholder return of 108.6%...

This article examines whether Petco Health and Wellness Company, at around US$3.62, may represent a bargain or a value trap by exploring what the current share price might indicate about the business. The stock has recently experienced sharp moves, with returns of 52.1% over the last 7 days, 44.2% over the last 30 days, 27.0% year to date and 51.5% over the last year. However, the 3 year and 5 year returns show declines of 63.1% and 84.4%, which tells a very different story. These swings...

In late 2025, Corcept Therapeutics received a Complete Response Letter from the FDA rejecting its New Drug Application for relacorilant on the grounds of insufficient evidence of effectiveness, prompting multiple securities class action lawsuits alleging the company misrepresented the drug’s regulatory prospects and prior FDA feedback. These lawsuits focus not just on the setback for relacorilant, but on claims that Corcept withheld repeated FDA concerns while continuing to promote the drug...

Old Republic International (NYSE:ORI) has appointed Doug Wordekemper as CEO of Old Republic Professional. The move is part of a broader organizational leadership change within the Professional division. The appointment brings a leader with extensive industry experience into a key role overseeing the Professional business. Old Republic International, through its Professional division, focuses on specialty insurance solutions for professional liability and related risks. Leadership changes in...

Subscriber milestone puts Karooooo (KARO) in focus Cartrack, a subsidiary of Karooooo (KARO), has surpassed two million active subscribers in South Africa. This milestone puts the group’s mobility SaaS model and customer-focused execution firmly on investors’ radar. See our latest analysis for Karooooo. Karooooo’s latest subscriber milestone lands after a period where the share price has moved steadily rather than sharply, with a 5.69% year to date share price return and a 19.93% one year...

If you are wondering whether WEX at around US$159.95 is priced fairly or offering value, you are not alone. This article is built to help you assess that question using several valuation tools. The stock has been relatively mixed recently, with a 7.8% return year to date and 3.8% over the last year, alongside a 4.3% decline over the past week and a 1.4% gain over the last 30 days. These movements can change how the market is thinking about its risk and opportunity. Recent coverage has...

LKQ stock performance context LKQ (LKQ) shares closed at $29.34, with the stock showing a 1 day return of 1.38% and a 7 day decline of 6.77%. This sets the stage for a closer look at its recent performance. See our latest analysis for LKQ. At the current share price of $29.34, LKQ’s 30 day share price return of a 13.96% decline sits alongside a 1 year total shareholder return of a 26.95% decline, pointing to fading momentum rather than a short term blip. If LKQ’s recent pullback has you...

Why Celldex Therapeutics (CLDX) is on investors’ radar today Celldex Therapeutics (CLDX) has drawn attention after recent trading, with shares last closing at $29.51 and showing mixed returns over the past week, month, past 3 months, and year. See our latest analysis for Celldex Therapeutics. Recent trading has been choppy, with a 30 day share price return of 28.30% and a 1 year total shareholder return of 44.52%, set against a weaker 3 year total shareholder return of 29.47% and a 5 year...

Recent share performance and business snapshot Titan America (TTAM) has drawn attention after a one month return showing a 16.1% decline, extending a past 3 months slide of 7.8%. This has prompted investors to reassess the cement and building materials producer. The Brussels based company reports annual revenue of US$1.65b and net income of US$178.46m, with recent revenue growth of 6.3% and net income growth of 13.7%. This has put a spotlight on how earnings support the current share...

Earlier this month, Jones Lang LaSalle unveiled its Accelerate 2030 plan, pairing new long-term financial targets with an enlarged share repurchase authorization of US$4.40 billion, including a US$200 million accelerated buyback. This combination of technology-led growth ambitions and a very large capital return commitment marks a meaningful shift in how JLL is positioning itself for clients and shareholders through 2030. Next, we’ll consider how JLL’s significantly expanded share buyback...

Setting the scene on U.S. Physical Therapy With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income. See our latest analysis for U.S. Physical Therapy. The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return...

Wix.com Ltd. recently reported its fourth-quarter 2025 results, showing revenue of US$524.27 million and a net loss of US$40.23 million, alongside full-year 2025 revenue of US$1.99 billion and net income of US$50.65 million. On the same day, Wix.com issued mid-teens percentage revenue growth guidance for both the first quarter and full year 2026 and secured a US$250,000,000 private placement featuring warrants and lock-up agreements with Durable Capital Partners and other investors,...

In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine. This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion...

Earlier in March, Federated Hermes announced that four of its investment strategies received LSEG Lipper Fund Awards 2026 US for consistently strong risk‑adjusted performance, while CEO J. Christopher Donahue is scheduled to present at the RBC Capital Markets Global Financial Institutions Conference 2026 in New York on March 11. This combination of third‑party recognition and high recent earnings growth and return on equity is sharpening attention on how effectively Federated Hermes converts...

In early March 2026, Clarivate Plc announced it had integrated its Cortellis Regulatory Intelligence data with Anthropic’s Claude via the open Model Context Protocol, giving biopharma, biotech, medtech and clinical research organizations context-aware access to authoritative regulatory data directly within their existing AI workflows. This move highlights how Clarivate is aiming to embed its validated regulatory content deeper into customers’ day-to-day decision processes, potentially...

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...

EHang Holdings Limited reported its fourth-quarter 2025 results on March 12, 2026, with sales rising to CNY 243.78 million and quarterly net income reaching CNY 10.49 million, while full-year 2025 revenue increased to CNY 509.50 million alongside a full-year net loss of CNY 230.54 million. The shift from a quarterly net loss in the prior year to profitability in Q4 2025, even as the full year remained loss-making, highlights a meaningful improvement in operating performance and cost...

Why Evercore (EVR) is on investors’ radar today Evercore (EVR) has drawn fresh attention after a period of mixed share performance, with a recent 0.4% daily gain that contrasts with weaker moves over the past week, month, and past 3 months. See our latest analysis for Evercore. That 0.4% 1 day share price gain comes after a tougher spell, with a 7.2% 7 day share price decline and a 23.6% year to date share price decline, even though the 1 year total shareholder return is 35.1% and the 3 year...

Wynn Resorts has resumed construction on its US$5.10 billion Wynn Al Marjan Island integrated resort in Ras Al Khaimah, UAE, after a brief security-related pause, while maintaining close coordination with US and UAE authorities to safeguard employees and operations. This restart reinforces Wynn’s push into the Middle East through a 40% stake in the project, marking the region’s first large-scale casino resort and expanding its luxury hospitality footprint beyond existing US and Asia...

If you are wondering whether Enova International at around US$134.11 is still offering value or already pricing in a lot of optimism, you are asking the right question for this stock. The share price has seen a 2.5% decline over the last 7 days and a 10.1% decline over the last 30 days, although the 1 year return sits at 44.8% and the 3 year return is 220.5%, with 5 year returns at 266.4%. Recent coverage of Enova International has focused on its position within the diversified financials...